alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 118 studies in Scientific reports · free to read (page 1 of 5) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Scientific reports 2019-12-13

We evaluated the performance of CSF biomarkers for predicting risk of clinical decline and conversion to dementia in non-demented patients with cognitive symptoms. 4 key findings →

Design: longitudinal study Participants: 619 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Scientific reports 2023-04-03

The Olink Proteomics panel of inflammation markers ( https://www.olink.com/products/inflammation/ ) will be used to evaluate 92 proteins associated with inflammatory diseases and related biological processes. 3 key findings →

Design: open-label trial Participants: 50 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

A comparison of machine learning methods for survival analysis of high-dimensional clinical data for dementia prediction

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Scientific reports 2020-11-23

Data collected from clinical trials and cohort studies, such as dementia studies, are often high-dimensional, censored, heterogeneous and contain missing information, presenting challenges to traditional statistical analysis. 1 key finding →

Design: cohort study Participants: 1,037 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Predicting Alzheimer's disease progression using multi-modal deep learning approach

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Scientific reports 2019-02-13

Alzheimer's disease (AD) is a progressive neurodegenerative condition marked by a decline in cognitive functions with no validated disease modifying treatment. 1 key finding →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Integrated genomic approaches identify major pathways and upstream regulators in late onset Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Scientific reports 2015-07-23

Previous studies have evaluated gene expression in Alzheimer's disease (AD) brains to identify mechanistic processes, but have been limited by the size of the datasets studied. 4 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The long-term neuroprotective effect of MIND and Mediterranean diet on patients with Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Scientific Reports 2025-09-24

Alzheimer's disease is a progressive neurodegenerative disorder with no cure, making preventive strategies crucial. 5 key findings →

Design: cohort study Participants: 1,500 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Machine Learning-based Individual Assessment of Cortical Atrophy Pattern in Alzheimer's Disease Spectrum: Development of the Classifier and Longitudinal Evaluation

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Scientific reports 2018-03-07

To develop a new method for measuring Alzheimer's disease (AD)-specific similarity of cortical atrophy patterns at the individual-level, we employed an individual-level machine learning algorithm. 5 key findings →

Design: longitudinal study Participants: 473 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Scientific reports 2020-06-08

Cerebrospinal fluid (CSF) biomarkers are useful in the diagnosis and the prediction of progression of several neurodegenerative diseases. 2 key findings →

Participants: 535 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

CSF GAP-43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Scientific reports 2022-10-17

To test whether cerebrospinal fluid (CSF) growth-associated protein 43 (GAP-43) concentration is elevated in Alzheimer's disease (AD) dementia and its associations with other hallmarks of AD, we examined the CSF GAP-43 measurements of 787 participants (245 cognitively normal (CN), 415 individuals with mild cognitive impairment (MCI) and 127 individuals with AD dementia) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. 4 key findings →

Design: longitudinal study Participants: 787 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association between urate-lowering therapies and cognitive decline in community-dwelling older adults

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Scientific reports 2022-09-12

Long-term use of urate-lowering therapies (ULT) may reduce inflammaging and thus prevent cognitive decline during aging. 3 key findings →

Design: randomized controlled trial Participants: 51 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Selecting the most important self-assessed features for predicting conversion to mild cognitive impairment with random forest and permutation-based methods

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Scientific reports 2020-11-26

Alzheimer's Disease is a complex, multifactorial, and comorbid condition. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Scientific reports 2019-02-21

A possible involvement of the gene IL1RAP (interleukin-1 receptor-associated protein) in the pathogenesis of Alzheimer's disease (AD) has been suggested in GWASs of cerebrospinal fluid (CSF) tau levels and longitudinal change in brain amyloid burden. 4 key findings →

Design: longitudinal study Participants: 3,446 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Harmonized prevalence estimates of dementia in Europe vary strongly with childhood education

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Scientific Reports 2025-04-23

Up-to-date, strictly cross-nationally comparable and nationally representative data on cognitive health are essential for our understanding of the dementia-related challenges in healthcare, to detect shortcomings in healthcare systems and to design effective prevention strategies. 1 key finding →

Participants: 47,773 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Knowledge and practice of healthy behaviors for dementia and stroke prevention in a United States cohort

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Scientific Reports 2025-04-30

At least 45% of dementia and 60% of stroke cases are due to modifiable risk factors and could in part be prevented through healthy behavior. 3 key findings →

Design: cross-sectional Participants: 1,478 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Effectiveness of a 52-week multidomain intervention to maintain cognitive function in patients with mild cognitive impairment: a randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Scientific Reports 2025-11-20

Mild cognitive impairment (MCI) increases the risk of dementia. 3 key findings →

Design: randomized controlled trial Participants: 84 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Diagnostic value of digital clock drawing test in comparison with CERAD neuropsychological battery total score for discrimination of patients in the early course of Alzheimer's disease from healthy individuals

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Scientific reports 2019-03-05

Our findings suggest that dCDT is a suitable screening tool to identify early cognitive dysfunction. 1 key finding →

Participants: 381 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed